These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24425288)

  • 1. Glycoprotein non-metastatic melanoma protein B as a predictive prognostic factor in clear-cell renal cell carcinoma following radical nephrectomy.
    Qin C; Liu Z; Yuan Y; Zhang X; Li H; Zhang C; Xu T; Wang X
    Mol Med Rep; 2014 Mar; 9(3):851-6. PubMed ID: 24425288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases.
    Heinzelmann J; Unrein A; Wickmann U; Baumgart S; Stapf M; Szendroi A; Grimm MO; Gajda MR; Wunderlich H; Junker K
    Ann Surg Oncol; 2014 Mar; 21(3):1046-54. PubMed ID: 24242678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-level S100A6 promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma.
    Lyu X; Li H; Ma X; Li X; Gao Y; Ni D; Shen D; Gu L; Wang B; Zhang Y; Zhang X
    Cell Biochem Biophys; 2015 Jan; 71(1):279-90. PubMed ID: 25120023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of glycoprotein non-metastatic melanoma protein B in clear-cell renal cell carcinoma and clinical implication thereof].
    He C; Qin C; Xu T; Yuan Y; Liu Z; Sheng Z; Hu F; Dun Y; Wang X
    Zhonghua Yi Xue Za Zhi; 2015 Aug; 95(30):2455-8. PubMed ID: 26711208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of human leukocyte antigen class I (HLA-I) is associated with poor prognosis in patients with clear cell renal cell carcinoma.
    Yuan J; Liu S; Yu Q; Lin Y; Bi Y; Wang Y; An R
    Acta Histochem; 2013 Jun; 115(5):470-4. PubMed ID: 23245688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.
    Rose AA; Grosset AA; Dong Z; Russo C; Macdonald PA; Bertos NR; St-Pierre Y; Simantov R; Hallett M; Park M; Gaboury L; Siegel PM
    Clin Cancer Res; 2010 Apr; 16(7):2147-56. PubMed ID: 20215530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma.
    Phuoc NB; Ehara H; Gotoh T; Nakano M; Yokoi S; Deguchi T; Hirose Y
    Urology; 2007 May; 69(5):843-8. PubMed ID: 17482919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
    Kusuda Y; Miyake H; Behnsawy HM; Fukuhara T; Inoue TA; Fujisawa M
    Urol Oncol; 2013 Jan; 31(1):42-50. PubMed ID: 21396851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of interleukin-11 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma.
    Pan D; Xu L; Liu H; Zhang W; Liu W; Liu Y; Fu Q; Xu J
    Cancer Sci; 2015 May; 106(5):592-7. PubMed ID: 25702890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma.
    Liu Y; Yang L; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
    Sci Rep; 2015 Nov; 5():16954. PubMed ID: 26599282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers.
    Minervini A; Di Cristofano C; Gacci M; Serni S; Menicagli M; Lanciotti M; Salinitri G; Rocca CD; Lapini A; Nesi G; Bevilacqua G; Minervini R; Carini M
    J Urol; 2008 Oct; 180(4):1284-9. PubMed ID: 18707725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma.
    Minardi D; Santoni M; Lucarini G; Mazzucchelli R; Burattini L; Conti A; Bianconi M; Scartozzi M; Milanese G; Primio RD; Montironi R; Cascinu S; Muzzonigro G
    Urol Oncol; 2015 Mar; 33(3):113.e1-7. PubMed ID: 25069421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of p21-activated kinase 6 expression in patients with clear cell renal cell carcinoma.
    Liu W; Liu H; Liu Y; Xu L; Zhang W; Zhu Y; Xu J; Gu J
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S575-83. PubMed ID: 24715215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis.
    Mignogna C; Staibano S; Altieri V; De Rosa G; Pannone G; Santoro A; Zamparese R; D'Armiento M; Rocchetti R; Mezza E; Nasti M; Strazzullo V; Montanaro V; Mascolo M; Bufo P
    BMC Cancer; 2006 Dec; 6():293. PubMed ID: 17177989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.
    Yardley DA; Weaver R; Melisko ME; Saleh MN; Arena FP; Forero A; Cigler T; Stopeck A; Citrin D; Oliff I; Bechhold R; Loutfi R; Garcia AA; Cruickshank S; Crowley E; Green J; Hawthorne T; Yellin MJ; Davis TA; Vahdat LT
    J Clin Oncol; 2015 May; 33(14):1609-19. PubMed ID: 25847941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
    Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
    Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy.
    Wotschofsky Z; Busch J; Jung M; Kempkensteffen C; Weikert S; Schaser KD; Melcher I; Kilic E; Miller K; Kristiansen G; Erbersdobler A; Jung K
    Clin Chim Acta; 2013 Feb; 416():5-10. PubMed ID: 23178446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of FOXO3a promotes tumor metastasis and is associated with metastasis-free survival of patients with clear cell renal cell carcinoma.
    Ni D; Ma X; Li HZ; Gao Y; Li XT; Zhang Y; Ai Q; Zhang P; Song EL; Huang QB; Fan Y; Zhang X
    Clin Cancer Res; 2014 Apr; 20(7):1779-90. PubMed ID: 24486593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma.
    Krambeck AE; Dong H; Thompson RH; Kuntz SM; Lohse CM; Leibovich BC; Blute ML; Sebo TJ; Cheville JC; Parker AS; Kwon ED
    Clin Cancer Res; 2007 Mar; 13(6):1749-56. PubMed ID: 17363528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.